Compare Adaptive Biotechnologies Corp (ADPT) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Yum! Brands, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $24.88 (market cap $4.04B), while Yum! Brands, Inc. trades at $149.2 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 9.8× Adaptive Biotechnologies Corp's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | YUM | |
|---|---|---|
Market Cap | $4.04B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $168.16 |
52-Week Low | $12.30 | $138.21 |
Enterprise Value | $4.10B | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
YUM Brands trades at $148.91, up 2.46% with recent earnings beats offset by food safety concerns. Technical indicators show bearish momentum with support at $141, while fundamentals reveal strong revenue growth to $8.21B in 2025 and net income of $1.56B. The company recently completed the $1.2B sale of Pizza Hut China, streamlining operations amid cyclospora outbreak impacts on Taco Bell sales.
YUM presents a mixed outlook with 37% analyst buy ratings and $174.60 price target suggesting 17% upside, but faces near-term headwinds from food safety investigations and consumer sentiment. Long-term growth depends on KFC/Taco Bell execution and digital strategy success amid elevated debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
